Observational studyHepatology (Baltimore, Md.)2021
Determination of Effective Albumin in Patients With Decompensated Cirrhosis: Clinical and Prognostic Implications.
Observational study in Hepatology (Baltimore, Md.), 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 46 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
46 citing papers in PubMed, 1 synthesis or guideline pooled it, 80 citations in OpenAlex.
- Effect of human albumin infusion on inflammation, oxidative stress, and prognosis in decompensated cirrhosis: a prospective cohort study with a meta-analysis.BMC gastroenterology · 2026Pooled it
- Artificial Liver Support Effectively Removes Immunosuppressive Bile Acids From Circulation in Patients With Severe Liver Failure: A Proof of Concept Study.Critical care explorations · 2026Trial
- Impact of early albumin therapy on 28-day survival in ICU patients with septic shock concurrent hypoalbuminemia: a retrospective analysis of combined clinical datasets.World journal of emergency medicine · 2026Article
- Not Just for Volume Anymore: New Indications for Albumin in Patients with Liver Disease.Digestive diseases and sciences · 2026Article
- Human serum albumin profiling by top-down analysis enables multi-class liver fibrosis staging: a cross-platform validation study.Scientific reports · 2026Article
- Mechanistic study of miR-148a-3p-mediated AMPK/mTOR/S6-dependent autophagy in hepatitis B virus replication.Virus genes · 2026Article
- Albumin-on-a-chip: binding profiling of circulating human albumin via selective immunocapture and real-time SPR analysis.Scientific reports · 2026Article
- Impact of albumin infusion on 30-day mortality in ICU patients with acute-on-chronic liver failure: a retrospective cohort using MIMIC-IV database.Clinical and experimental medicine · 2026Article
- Post-Translational Changes in Serum Albumin in Patients with Alcohol-Associated Hepatitis.International journal of molecular sciences · 2026Article
- High CALLY index is independently associated with lower odds of preserved ratio impaired spirometry (PRISm) and provides incremental predictive value: a retrospective observational study.Frontiers in medicine · 2026Article
- Binding and transport functions of human serum albumin and its clinical implications in liver disease: a narrative review.Translational gastroenterology and hepatology · 2026Review
- Association between serum albumin to creatinine ratio and mortality risk in patients with acute-on-chronic liver failure.Scientific reports · 2025Article
- A nomogram for assessing the risk of MAFLD based on the albumin-to-gamma-glutamyl transferase ratio.European journal of medical research · 2025Article
- Three-year outcomes of tumor necrosis factor alpha inhibitor therapy in rheumatoid arthritis patients with elevated liver enzymes.World journal of hepatology · 2025Article
- Association between lactate-to-albumin ratio and all-cause mortality in critically ill cirrhotic patients with sepsis: a retrospective analysis of the MIMIC-IV database.BMC gastroenterology · 2025Article
- Analysis of the prognostic efficacy of syndecan-1 for patients with ACLF and its functional role in liver regeneration.BMC medicine · 2025Article
- The association of advanced lung cancer inflammation index with non-alcoholic fatty liver disease in NHANES 2017-2020.Frontiers in medicine · 2025Article
- Association between red cell distribution width-to-albumin ratio and all-cause mortality in critically ill cirrhotic patients with sepsis: a retrospective analysis of the MIMIC-IV database.Frontiers in medicine · 2025Article
- Proteomic analysis of mouse liver lesions at all three stages of Echinococcus granulosus infection.PLoS neglected tropical diseases · 2024Article
- Artificial intelligence-based evaluation of prognosis in cirrhosis.Journal of translational medicine · 2024Review
Corrections and comments
- Commented on by
Authors and funding
18 authors at 4 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
BACKGROUND AND
aimsCirculating albumin in cirrhosis can be dysfunctional because of accumulating structural damages, leading to the concept of effective albumin concentration (eAlb), referring to the albumin portion presenting structural and functional integrity. We aimed to estimate eAlb in patients with decompensated cirrhosis and analyze its relationships with albumin function and clinical outcomes as compared to total albumin concentration (tAlb). APPROACH AND
resultsWe evaluated 319 patients with cirrhosis hospitalized for acute decompensation (AD) with and without acute-on-chronic liver failure (ACLF) and 18 age- and sex-comparable outpatients with compensated cirrhosis. tAlb was quantified by standard assay, whereas eAlb was estimated combining liquid chromatography/electrospray ionization/mass spectrometry and standard methods. Albumin binding and detoxification efficiency were evaluated by electron paramagnetic resonance analysis. Circulating albumin in patients with decompensated cirrhosis displayed multiple structural abnormalities, with reversible oxidation and glycation being the most frequent. As a result, eAlb progressively declined with the worsening of cirrhosis and was superior to tAlb in stratifying patients between compensated cirrhosis, AD, and ACLF, as well as patients with and without complications. Moreover, eAlb, but not tAlb, was closely associated with binding capacities in ACLF. Finally, eAlb at admission predicted the occurrence of ACLF within 30 days and mortality at 90 days better than tAlb.
conclusionsThis large, observational study provides the evidence in patients with decompensated cirrhosis that eAlb can be quantified and differentiated from tAlb routinely measured in clinical practice. As compared to tAlb, eAlb is more closely associated with disease severity and albumin dysfunction and carries a greater prognostic power. These results prompt future research assessing eAlb as a biomarker for predicting prognosis and treatment response.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.